PT  - JOURNAL ARTICLE
AU  - Oddsson, Lars IE
AU  - Bisson, Teresa
AU  - Cohen, Helen S
AU  - Iloputaife, Ikechukwu
AU  - Jacobs, Laura
AU  - Kung, Doris
AU  - Lipsitz, Lewis A
AU  - Manor, Brad
AU  - McCracken, Patricia
AU  - Rumsey, Yvonne
AU  - Wrisley, Diane M
AU  - Koehler-McNicholas, Sara R
TI  - Extended Effects of a Wearable Sensory Prosthesis on Gait, Balance Function and Falls After 26 Weeks of Use in Persons with Peripheral Neuropathy and High Fall Risk – The walk2Wellness Trial
AID  - 10.1101/2022.04.28.22274328
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.28.22274328
4099  - http://medrxiv.org/content/early/2022/04/28/2022.04.28.22274328.short
4100  - http://medrxiv.org/content/early/2022/04/28/2022.04.28.22274328.full
AB  - Background We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins®, a wearable lower limb sensory prosthesis that provides directional tactile stimuli related to plantar pressure measurements during standing and walking (RxFunction Inc., MN, USA). Here, we report 26-week outcomes and compare pre- and in-study fall rates. We expected improvements in outcomes and reduced fall rates reported after 10 weeks of use to be sustained.Methods Participants had clinically diagnosed PN with impaired plantar sensation, high fall risk (Functional Gait Assessment, FGA score <23) and ability to sense tactile stimuli above the ankle at the location of the device. Additional outcomes included 10m Gait Speed, Timed Up&Go (TUG), Four-Stage Balance Test, and self-reported outcomes, including Activities-Specific Balance Confidence scale and Vestibular Disorders Activities of Daily Living Scale. Participants tracked falls using a calendar.Results We assessed falls and self-reported outcomes from 44 individuals after 26 weeks of device use; 30 of them conducted in-person testing of clinical outcomes. Overall, improvements in clinical outcomes seen at 10 weeks of use remained sustained at 26 weeks with statistically significant increases compared to baseline seen in FGA scores (from 15.0 to 19.2), self-selected gait speed (from 0.89 m/s to 0.97 m/s), and 4-Stage Balance Test (from 25.6s to 28.4s), indicating a decrease in fall risk. Non-significant improvements were observed in TUG and fast gait speed. Overall, 39 falls were reported; 31 of them did not require medical treatment and four caused severe injury. Participants who reported falls over 6 months prior to the study had a 43% decrease in fall rate during the study as compared to self-report 6-month pre-study (11.8 vs. 6.7 falls/1000 patient days, respectively, p<0.004), similar to the 46% decrease reported after 10 weeks of use.Conclusion A wearable sensory prosthesis can improve outcomes of gait and balance function and substantially decreases incidence of falls during long-term use. The sustained long-term benefits in clinical outcomes reported here lessen the likelihood that improvements are placebo effects.Trial registration ClinicalTrials.gov (#NCT03538756)Competing Interest StatementMixed competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LO is an inventor of the technology, Co-Founder of RxFunction, a shareholder in the company, serves on its Board of Directors and is an employee of the company. LJ and YR are employees of RxFunction and LJ is a shareholder. The remaining authors received grant funding from RxFunction for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT03538756Funding StatementThe walk2Wellness trial was completely funded by RxFunction Inc. Participating sites have received funding from RxFunction to conduct research activities related to the trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by Advarra IRB (formerly Quorum Review IRB), serving as the Institutional Review Board (IRB) of record for three of the participating sites under the study protocol. The three sites include Baylor College of Medicine, Houston, TX; Hebrew SeniorLife, a Harvard Medical School Affiliate, Boston, MA; and M Health Fairview, Minneapolis, MN. The IRB Subcommittee, the Subcommittee on Research Safety, and the Research and Development Committee of the Minneapolis VA Health Care System (MVAHCS) also approved the trial. The study is registered on ClinicalTrials.gov (#NCT03538756). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. The patients/participants provided their written informed consent to participate in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data supporting the conclusions of this article will be made available to qualified researchers by the authors, without undue reservation